AGOURA HILLS, Calif. — May 6, 2026 — Leads & Copy — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has entered into a strategic asset transfer agreement with Lunai Bioworks, Inc. for its N2B (nose-to-brain) delivery system. The agreement establishes an initiative focused on biodefense and Alzheimer’s disease (AD).
In return, Oncotelic received $12.5 million in Lunai Bioworks Series B Convertible Preferred Stock. Oncotelic continues to evaluate additional partnerships to further monetize its portfolio while maintaining strategic control over core assets.
Under the terms of the agreement, Oncotelic has granted Lunai Bioworks worldwide rights to the N2B delivery system IP portfolio within defined fields, specifically biodefense medical countermeasures and Alzheimer’s disease only.
The N2B delivery system represents a device-enabled therapeutic approach designed to deliver agents directly to the central nervous system. It offers a potential alternative to traditional intramuscular or systemic delivery methods. By bypassing the blood-brain barrier, the platform enables faster onset of action and improved targeting of neurological pathways critical in both acute biodefense scenarios and chronic neurodegenerative diseases.
This approach is particularly relevant for medical countermeasures against chemical, biological, and viral threats, where rapid CNS intervention can significantly impact survival and long-term neurological outcomes. The technology aligns with Department of War interests in traumatic brain injury (TBI), acute neuroprotection, chemical and biological threat countermeasures, pain management, and neurodegenerative conditions impacting service members and veterans.
The collaboration leverages Oncotelic’s experience in biodefense and CNS therapeutics. Dr. Vuong Trieu (CEO) has led a BARDA-supported program advancing therapies for COVID-related conditions. Michael French (Head of Business Development) brings U.S. Army Medical Intelligence experience in chemical and biological threat environments. Steve King (Board Member) previously led DTRA-funded biodefense programs focused on antiviral platforms.
This combined expertise integrates clinical development, biodefense strategy, and operational deployment readiness, supporting both government-funded opportunities and commercial CNS applications.
The consideration for the agreement is $12.5 million in Lunai Bioworks Series B Convertible Preferred Stock. The structure is a field-specific IP assignment for the N2B delivery system, with indications for biodefense (medical countermeasures) and Alzheimer’s disease.
Management believes this collaboration positions Oncotelic to participate in biodefense funding initiatives (e.g., BARDA, DOD), advance rapid-response CNS therapeutic frameworks, and expand into large and growing neurodegenerative disease markets.
Oncotelic Therapeutics, Inc. is focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The Company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The Company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.
Source: Oncotelic Therapeutics, Inc.
